Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes

      Background

      Niacin compounds lower serum phosphorus concentrations in patients with end-stage renal disease.

      Methodology

      We evaluated the impact of extended release niacin, given in fixed-dose combination with laropiprant, a specific inhibitor of prostaglandin-mediated, niacin-induced flushing, versus placebo, on serum phosphorus concentrations measured serially (at weeks 0, 4, 8, 12, 18, 24, 30, and 36) during a 36-week randomized, controlled trial. All subjects had a confirmed diagnosis of type 2 diabetes (n = 446 niacin/laropiprant; n = 339 placebo). Estimated glomerular filtration rate ranged from 36 to 184 mL/min/1.73 m2, with n = 111 (14.1%) having a value <60 mL/min/1.73 m2. Subjects received one tablet daily of extended-release niacin/laropiprant (1g niacin/ 20 mg laropiprant) for the first 4 weeks, and 2 tablets once daily, thereafter, or matched placebo. Niacin lowered serum phosphorus concentrations by 0.36 mg/dL (95% CI: −0.40, −0.31; P < .001), relative to placebo, from baseline values of 3.57 and 3.56 mg/dL in the niacin and placebo groups, respectively. Subgroup analyses revealed no evidence for phosphorus-lowering effect modification by these baseline variables: glomerular filtration rate <60 (n = 111;14.1%) vs ≥60 mL/min/m2 (n = 674; 85.9%); phosphorus ≤3.5 mg/dL (n = 392; 49.9%) vs >3.5 mg/dL (n = 393; 50.1%); or prior statin use (n = 618; 78.7%) vs nonuse (n = 167; 21.3%).

      Conclusions and Implications

      These data confirm that niacin’s phosphorus-lowering effects—which may have therapeutic implications for the management of hyperphosphatemia and possible prevention of cardiorenal outcomes in renal disease—extend across a broad spectrum of renal function in type 2 diabetics without stage 4 or 5 chronic kidney disease (a glomerular filtration rate ≥30 mL/min/1.73 m2).

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. 2008 United States Renal Data System Report III. Table C.1, p.55, “Counts of new end-stage renal disease patients with medical evidence forms.” Available at: http://www.usrds.org/2008/ref/C_Patient_Characteristics_08.pdf. Accessed May 16th, 2011.

        • National Kidney Foundation
        Clinical practice guidelines for bone metabolism and disease in chronic kidney disease.
        Am J Kidney Dis. 2003; 42: 1-201
        • Ketteler M.
        • Floege J.
        Calcification and the usual suspect phosphate: Still guilty but there are other guys behind the scenes.
        Nephrol Dial Transplant. 2006; 21: 33-35
        • Cannata-Andia J.B.
        • Rodriguez-Garcia M.
        • Carrillo-Lopez N.
        • Naves-Diaz M.
        • Diaz-Lopez B.
        Vascular calcifications: pathogenesis, management, and impact on clinical outcomes.
        J Am Soc Nephrol. 2006; 17: S267-S273
        • Suzuki T.
        • Yonemura K.
        • Maruyama T.
        • Takahashi T.
        • Takita T.
        • Furuhashi M.
        • et al.
        Impact of serum parathyroid hormone concentration and its regulatory factors on arterial stiffness in patients undergoing maintenance hemodialysis.
        Blood Purif. 2004; 22: 293-297
        • Porter C.J.
        • Stavroulopoulos A.
        • Roe S.D.
        • Pointon K.
        • Cassidy M.J.
        Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes.
        Nephrol Dial Transplant. 2007; 22: 3208-3213
        • Block G.A.
        • Hulbert-Shearon T.E.
        • Levin N.W.
        • Port F.K.
        Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
        Am J Kidney Dis. 1998; 1: 607-617
        • Ganesh S.K.
        • Stack A.G.
        • Levin N.W.
        • Hulbert-Shearon T.
        • Port F.K.
        Association of elevated serum PO4, Ca X PO4 product, and parathyroid hormone with cardiac mortality risk in hemodialysis patients.
        J Am Soc Nephrol. 2001; 12: 2131-2138
        • Kestenbaum B.
        • Sampson J.N.
        • Rudser K.D.
        • Patterson D.J.
        • Seliger S.L.
        • Young B.
        • et al.
        Serum phosphate levels and mortality risk among people with chronic kidney disease.
        J Am Soc Nephrol. 2005; 16: 520-528
        • Menon V.
        • Greene T.
        • Pereira A.A.
        • Wang X.
        • Beck G.J.
        • Kusek J.W.
        • et al.
        Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.
        Am J Kidney Dis. 2005; 46: 455-463
        • Melamed M.L.
        • Eustace J.A.
        • Plantinga L.
        • Jaar B.G.
        • Fink N.E.
        • Coresh J.
        • et al.
        Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.
        Kidney Int. 2006; 70: 351-357
        • Levin A.
        • Djurdjev O.
        • Beaulieu M.
        • Er L.
        Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.
        Am J Kidney Dis. 2008; 52: 661-671
        • Amann K.
        • Tornig J.
        • Kugel B.
        • Gross M.L.
        • Tyralla K.
        • El- Shakmak A.
        • et al.
        Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia.
        Kidney Int. 2003; 63: 1296-1301
        • Chonchol M.
        • Dale R.
        • Schrier R.W.
        • Estacio R.
        Serum phosphorus and cardiovascular mortality in type 2 diabetes.
        Am J Med. 2009; 122: 380-386
        • Chertow G.M.
        • Burke S.K.
        • Raggi P.
        Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
        Kidney Int. 2002; 62: 245-252
        • Block G.A.
        • Spiegel D.M.
        • Ehrlich J.
        • Mehta R.
        • Lindbergh J.
        • Dreisbach A.
        • et al.
        Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
        Kidney Int. 2005; 68: 1815-1824
        • Galassi A.
        • Spiegel D.M.
        • Bellasi A.
        • Block G.A.
        • Raggi P.
        Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders.
        Nephrol Dial Transplant. 2006; 21: 3215-3222
        • Chiu Y.W.
        • Teitelbaum I.
        • Misra M.
        • de Leon E.M.
        • Adzize T.
        • Mehrotra R.
        Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.
        Clin J Am Soc Nephrol. 2009; 4: 1089-1096
        • Coladonato J.A.
        Control of hyperphosphatemia among patients with ESRD.
        J Am Soc Nephrol. 2005; 16: S107-S114
        • Joy M.S.
        • Finn W.F.
        Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
        Am J Kidney Dis. 2003; 42: 96-107
        • Behets G.J.
        • Dams G.
        • Vercauteren S.R.
        • Damment S.J.
        • Bouillon R.
        • De Broe M.E.
        • et al.
        Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?.
        J Am Soc Nephrol. 2004; 15: 2219-2228
        • Qunibi W.Y.
        • Hootkins R.E.
        • McDowell L.L.
        • Meyer M.S.
        • Simon M.
        • Garza R.O.
        • et al.
        Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study).
        Kidney Int. 2004; 65: 1914-1926
        • Lacour B.
        • Lucas A.
        • Auchere D.
        • Ruellan N.
        • de Serre Patey N.M.
        • Drueke T.B.
        Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
        Kidney Int. 2005; 67: 1062-1069
        • Pennell P.
        • Leclercq B.
        • Delahunty M.I.
        • Walters B.A.
        The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
        Clin Nephrol. 2006; 66: 336-347
        • Sampathkumar K.
        Niacin and analogs for phosphate control in dialysis—perspective from a developing country.
        Int Urol Nephrol. 2009; 41: 813-918
        • Cheng S.C.
        • Young D.O.
        A Randomized, double blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
        Clin J Am Soc Nephrol. 2008; 3: 1131-1138
        • Young D.O.
        • Cheng S.C.
        • Delmez J.A.
        • Coyne D.W.
        The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients.
        Perit Dial Int. 2009; 29: 562-567
        • Maccubbin D.
        • Tipping D.
        • Kuznetsova O.
        • Hanlon W.A.
        • Bostom A.G.
        Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
        Clin J Am Soc Nephrol. 2010; 5: 582-589
        • MacLean A.
        • McKenney J.
        • Scott R.
        • Brinton E.
        • Bays H.
        • Giezek H.
        • et al.
        Lipid-altering efficacy and tolerability of ER niacin/laropiprant in type 2 diabetes mellitus patients.
        Euro Heart J. 2009; 30 (P1733): 298
        • MacLean A.
        • McKenney J.M.
        • Scott R.
        • Brinton E.
        • Bays H.E.
        • Mitchel Y.B.
        • et al.
        Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus.
        Br J Cardiol. 2011; 18: 37-45
        • Block G.A.
        • Persky M.S.
        • Ketteler M.
        • Kestenbaum B.
        • Thadhani R.
        • Kooienga L.
        • et al.
        A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology.
        Hemodial Int. 2009; 13: 260-262
        • Isakova T.
        • Gutiérrez O.M.
        • Wolf M.
        A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease.
        Kidney Int. 2009; 76: 705-716
        • McKenney J.
        • Bays H.
        • Koren M.
        • Ballantyne C.M.
        • Paolini J.F.
        • Mitchel Y.
        • et al.
        Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
        J Clin Lipidol. 2010; 4: 105-112
        • Portale A.A.
        Blood calcium, phosphorus, and magnesium.
        in: Favus M.J. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Lippincott, Williams & Wilkins, Philadelphia, PA1999: 105-118
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • Zhang Y.L.
        • Castro 3rd, A.F.
        • Feldman H.I.
        • et al.
        CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Katai K.
        • Miyamoto K.
        • Kishida S.
        • Segawa H.
        • Nii T.
        • Tanaka H.
        • et al.
        Regulation of intestinal Na-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3.
        Biochem J. 1999; 343: 705-712
        • Katai K.
        • Tanaka H.
        • Tatsumi S.
        • Fukunaga Y.
        • Genjida K.
        • Morita K.
        • et al.
        Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine.
        Nephrol Dial Transplant. 1999; 14: 1195-1201
        • Kuboyama N.
        • Watanabe Y.
        • Yamaguchi M.
        • Sato K.
        • Suzuki T.
        • Akiba T.
        Effects of niceritrol on faecal and urinary phosphate excretion in normal rats.
        Nephrol Dial Transplant. 1999; 14: 610-614
        • Eto N.
        • Miyata Y.
        • Ohno H.
        • Yamashita T.
        Nicotinamide prevents the development of hyperphosphatemia by suppressing the intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure.
        Nephrol Dial Transplant. 2005; 20: 1378-1384
        • Sabbagh Y.
        • O’Brien S.P.
        • Song W.
        • Boulanger J.H.
        • Stockmann A.
        • Arbeeny C.
        • et al.
        Intestinal Npt2b plays a major role in phosphate absorption and homeostasis.
        J Am Soc Nephrol. 2010; 20: 2348-2358
        • Knopp R.H.
        • Alagona P.
        • Davidson M.
        • Goldberg A.C.
        • Kafonek S.D.
        • Kashyap M.
        • et al.
        Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
        Metabolism. 1998; 47: 1097-1104
        • Capuzzi D.M.
        • Guyton J.R.
        • Morgan J.M.
        • Goldberg A.C.
        • Kreisberg R.A.
        • Brusco O.A.
        • et al.
        Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
        Am J Cardiol. 1998; 82: 74U-81U
        • Grundy S.M.
        • Vega G.L.
        • McGovern M.E.
        • Tulloch B.R.
        • Kendall D.M.
        • Fitz-Patrick D.
        • et al.
        Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
        Arch Intern Med. 2002; 162: 1568-1576
        • Canner P.L.
        • Furberg C.D.
        • Terrin M.L.
        • McGovern M.E.
        Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
        Am J Cardiol. 2005; 95: 254-257
        • Canner P.L.
        • Furberg C.D.
        • McGovern M.E.
        Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
        Am J Cardiol. 2006; 97: 477-479
        • Tonelli M.
        • Sacks F.
        • Pfeffer M.
        • Gao Z.
        • Curhan G.
        Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.
        Circulation. 2005; 112: 2627-2633
        • Isakova T.
        • Gutiérrez O.M.
        • Smith K.
        • Epstein M.
        • Keating L.K.
        • Jüppner H.
        • et al.
        Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
        Nephrol Dial Transplant. 2011; 26: 584-591
        • Oliveira R.B.
        • Cancela A.L.
        • Graciolli F.G.
        • Dos Reis L.M.
        • Draibe S.A.
        • Cuppari L.
        • et al.
        Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy?.
        Clin J Am Soc Nephrol. 2010; 5: 286-291
        • Bruckert E.
        • Labreuche J.
        • Amarenco P.
        Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis.
        Atherosclerosis. 2010; 210: 353-361
        • Coca S.G.
        • Krumholz H.M.
        • Garg A.X.
        • Parikh C.R.
        Under-representation of renal disease in randomized controlled trials of cardiovascular disease.
        JAMA. 2006; 296: 1377-1384